Cargando…

High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers

OBJECTIVES: Since early detection improves overall survival in lung cancer, identification of screening biomarkers for patients at risk represents an area of intense investigation. Tumor liberated protein (TLP) has been previously described as a tumor-associated antigen (complex) present in the sera...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Alessandra, Voigtlaender, Minna, Klose, Hans, Schlüter, Hartmut, Schön, Gerhard, Loges, Sonja, Paolini, Moreno, Bokemeyer, Carsten, Reck, Martin, Tarro, Giulio, Binder, Mascha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724438/
https://www.ncbi.nlm.nih.gov/pubmed/31534455
http://dx.doi.org/10.1155/2019/8970645
_version_ 1783448993231011840
author Rossi, Alessandra
Voigtlaender, Minna
Klose, Hans
Schlüter, Hartmut
Schön, Gerhard
Loges, Sonja
Paolini, Moreno
Bokemeyer, Carsten
Reck, Martin
Tarro, Giulio
Binder, Mascha
author_facet Rossi, Alessandra
Voigtlaender, Minna
Klose, Hans
Schlüter, Hartmut
Schön, Gerhard
Loges, Sonja
Paolini, Moreno
Bokemeyer, Carsten
Reck, Martin
Tarro, Giulio
Binder, Mascha
author_sort Rossi, Alessandra
collection PubMed
description OBJECTIVES: Since early detection improves overall survival in lung cancer, identification of screening biomarkers for patients at risk represents an area of intense investigation. Tumor liberated protein (TLP) has been previously described as a tumor-associated antigen (complex) present in the sera from lung cancer patients. Here, we set out to identify the nature of TLP to develop this as a potential biomarker for lung cancer screening. MATERIALS AND METHODS: Beginning from the peptide epitope RTNKEASI previously identified from the TLP complex, we produced a rabbit anti-RTNKEASI serum and evaluated it in the lung cancer cell line A549 by means of immunoblot and peptide completion assay (PCA). The TLP sequence identification was conducted by mass spectrometry. The detected protein was, then, analyzed in patients with non-small cell lung cancer (NSCLC) and benign lung pathologies and healthy donors, by ELISA. RESULTS: The anti-RTNKEASI antiserum detected and immunoprecipitated a 55 kDa protein band in the lysate of A549 cells identified as aldehyde dehydrogenase isoform 1A1, revealing the molecular nature of at least one component of the previously described TLP complex. Next, we screened blood samples from a non-tumor cohort of 26 patients and 45 NSCLC patients with different disease stages for the presence of ALDH1A1 and global ALDH. This analysis indicated that serum positivity was highly restricted to patients with NSCLC (ALDH p < 0.001; ALDH1A1 p=0.028). Interestingly, the global ALDH test resulted positive in more NSCLC samples compared to the ALDH1A1 test, suggesting that other ALDH isoforms might add to the sensitivity of the assay. CONCLUSION: Our data indicate that ALDH levels are elevated in the sera of NSCLC patients, even with early stage disease, and may thus be evaluated as part of a marker panel for non-invasive detection of NSCLC.
format Online
Article
Text
id pubmed-6724438
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-67244382019-09-18 High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers Rossi, Alessandra Voigtlaender, Minna Klose, Hans Schlüter, Hartmut Schön, Gerhard Loges, Sonja Paolini, Moreno Bokemeyer, Carsten Reck, Martin Tarro, Giulio Binder, Mascha J Oncol Research Article OBJECTIVES: Since early detection improves overall survival in lung cancer, identification of screening biomarkers for patients at risk represents an area of intense investigation. Tumor liberated protein (TLP) has been previously described as a tumor-associated antigen (complex) present in the sera from lung cancer patients. Here, we set out to identify the nature of TLP to develop this as a potential biomarker for lung cancer screening. MATERIALS AND METHODS: Beginning from the peptide epitope RTNKEASI previously identified from the TLP complex, we produced a rabbit anti-RTNKEASI serum and evaluated it in the lung cancer cell line A549 by means of immunoblot and peptide completion assay (PCA). The TLP sequence identification was conducted by mass spectrometry. The detected protein was, then, analyzed in patients with non-small cell lung cancer (NSCLC) and benign lung pathologies and healthy donors, by ELISA. RESULTS: The anti-RTNKEASI antiserum detected and immunoprecipitated a 55 kDa protein band in the lysate of A549 cells identified as aldehyde dehydrogenase isoform 1A1, revealing the molecular nature of at least one component of the previously described TLP complex. Next, we screened blood samples from a non-tumor cohort of 26 patients and 45 NSCLC patients with different disease stages for the presence of ALDH1A1 and global ALDH. This analysis indicated that serum positivity was highly restricted to patients with NSCLC (ALDH p < 0.001; ALDH1A1 p=0.028). Interestingly, the global ALDH test resulted positive in more NSCLC samples compared to the ALDH1A1 test, suggesting that other ALDH isoforms might add to the sensitivity of the assay. CONCLUSION: Our data indicate that ALDH levels are elevated in the sera of NSCLC patients, even with early stage disease, and may thus be evaluated as part of a marker panel for non-invasive detection of NSCLC. Hindawi 2019-08-22 /pmc/articles/PMC6724438/ /pubmed/31534455 http://dx.doi.org/10.1155/2019/8970645 Text en Copyright © 2019 Alessandra Rossi et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Rossi, Alessandra
Voigtlaender, Minna
Klose, Hans
Schlüter, Hartmut
Schön, Gerhard
Loges, Sonja
Paolini, Moreno
Bokemeyer, Carsten
Reck, Martin
Tarro, Giulio
Binder, Mascha
High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers
title High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers
title_full High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers
title_fullStr High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers
title_full_unstemmed High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers
title_short High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers
title_sort high aldehyde dehydrogenase levels are detectable in the serum of patients with lung cancer and may be exploited as screening biomarkers
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724438/
https://www.ncbi.nlm.nih.gov/pubmed/31534455
http://dx.doi.org/10.1155/2019/8970645
work_keys_str_mv AT rossialessandra highaldehydedehydrogenaselevelsaredetectableintheserumofpatientswithlungcancerandmaybeexploitedasscreeningbiomarkers
AT voigtlaenderminna highaldehydedehydrogenaselevelsaredetectableintheserumofpatientswithlungcancerandmaybeexploitedasscreeningbiomarkers
AT klosehans highaldehydedehydrogenaselevelsaredetectableintheserumofpatientswithlungcancerandmaybeexploitedasscreeningbiomarkers
AT schluterhartmut highaldehydedehydrogenaselevelsaredetectableintheserumofpatientswithlungcancerandmaybeexploitedasscreeningbiomarkers
AT schongerhard highaldehydedehydrogenaselevelsaredetectableintheserumofpatientswithlungcancerandmaybeexploitedasscreeningbiomarkers
AT logessonja highaldehydedehydrogenaselevelsaredetectableintheserumofpatientswithlungcancerandmaybeexploitedasscreeningbiomarkers
AT paolinimoreno highaldehydedehydrogenaselevelsaredetectableintheserumofpatientswithlungcancerandmaybeexploitedasscreeningbiomarkers
AT bokemeyercarsten highaldehydedehydrogenaselevelsaredetectableintheserumofpatientswithlungcancerandmaybeexploitedasscreeningbiomarkers
AT reckmartin highaldehydedehydrogenaselevelsaredetectableintheserumofpatientswithlungcancerandmaybeexploitedasscreeningbiomarkers
AT tarrogiulio highaldehydedehydrogenaselevelsaredetectableintheserumofpatientswithlungcancerandmaybeexploitedasscreeningbiomarkers
AT bindermascha highaldehydedehydrogenaselevelsaredetectableintheserumofpatientswithlungcancerandmaybeexploitedasscreeningbiomarkers